KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $4.0 million.

  • Bionano Genomics' Cost of Revenue fell 7247.06% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 5426.87%. This contributed to the annual value of $30.4 million for FY2024, which is 1448.59% up from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Cost of Revenue is $4.0 million, which was down 7247.06% from $3.3 million recorded in Q2 2025.
  • Bionano Genomics' Cost of Revenue's 5-year high stood at $14.5 million during Q3 2024, with a 5-year trough of $2.1 million in Q1 2021.
  • Over the past 5 years, Bionano Genomics' median Cost of Revenue value was $5.2 million (recorded in 2022), while the average stood at $5.5 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 30082.92% in 2021, then plummeted by 7247.06% in 2025.
  • Over the past 5 years, Bionano Genomics' Cost of Revenue (Quarter) stood at $6.1 million in 2021, then rose by 5.72% to $6.4 million in 2022, then grew by 29.22% to $8.3 million in 2023, then tumbled by 42.7% to $4.7 million in 2024, then dropped by 15.78% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $3.3 million for Q2 2025, and $3.5 million during Q1 2025.